Related Experiment Video
Updated: Apr 18, 2026
10:36
In Vitro Imaging and Quantification of the Drug Targeting Efficiency of Fluorescently Labeled GnRH Analogues
Published on: March 21, 2017
8.1K
GnRH-antagonist programming versus GnRH agonist protocol: a randomized trial
Anat Hershko Klement1, Arie Berkovitz1, Amir Wiser1
1The IVF Unit, Department of Obstetrics and Gynecology, Meir Medical Center, 59 Tschernihovsky St., Kfar Saba 44299, Israel.
European Journal of Obstetrics, Gynecology, and Reproductive Biology
|January 17, 2015
Summary
This study shows that programming in vitro fertilization (IVF) gonadotropin-releasing hormone (GnRH) antagonist cycles can successfully avoid weekend oocyte retrieval without compromising outcomes. This approach offers flexibility in scheduling IVF procedures.
Area of Science:
- Reproductive Endocrinology
- In Vitro Fertilization (IVF)
Background:
- Weekend oocyte retrieval in IVF can pose logistical challenges.
- Gonadotropin-releasing hormone (GnRH) antagonist protocols offer flexibility in cycle management.
Purpose of the Study:
- To evaluate the efficacy of programming GnRH antagonist cycles to avoid weekend oocyte retrieval.
- To assess if programmed follicular estrogen can be used in GnRH antagonist protocols.
Main Methods:
- A preliminary randomized clinical trial compared a programmed GnRH antagonist protocol with a standard GnRH agonist protocol.
- Patients received estradiol valerate to facilitate Friday follicular development and subsequent stimulation.
Main Results:
- No significant differences in cycle dynamics, oocyte yield, fertilization, embryo quality, or pregnancy rates were observed.
- Only one patient in the treatment group required weekend oocyte retrieval.
- A significant difference was noted in the number of follicles ≥18 mm on hCG administration day.
Conclusions:
- Follicular estrogen programming in GnRH antagonist cycles is feasible and does not negatively impact IVF outcomes.
- This strategy provides reassurance for achieving scheduling goals and avoiding weekend retrievals.
Related Concept Videos
01:25Drug-Receptor Interaction: Agonist
4.9K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
4.9K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
788
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
788
01:29Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
1.2K
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
1.2K
01:24Glucagon-like Receptor Agonists
1.4K
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
1.4K
01:28Drug-Receptor Interaction: Antagonist
5.7K
An antagonist is a drug that binds strongly to a receptor without activating it. An antagonist prevents other molecules, such as neurotransmitters or hormones, from binding to the receptor and triggering a cellular response. Such interaction effectively hinders the normal physiological processes mediated by the receptor, resulting in various pharmacological effects depending on the specific receptor targeted.
Antagonists can be classified as competitive or noncompetitive based on their...
Antagonists can be classified as competitive or noncompetitive based on their...
5.7K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K